Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

被引：65
作者：
Borella, Fulvio [1 ]
Ghisoni, Eleonora [2 ,3 ]
Giannone, Gaia [2 ,3 ]
Cosma, Stefano [1 ]
Benedetto, Chiara [1 ]
Valabrega, Giorgio [2 ,3 ]
Katsaros, Dionyssios [1 ]
机构：
[1] Univ Turin, Dept Surg Sci, Gynecol & Obstet 1, I-10126 Turin, Italy
[2] Univ Torino, Dept Oncol, I-10060 Turin, Italy
[3] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, Italy
来源：
DIAGNOSTICS | 2020年 / 10卷 / 03期
关键词：
Ovarian cancer; immunotherapy; immune checkpoint inhibitors; safety; biomarkers; clinical trials; TUMOR-INFILTRATING LYMPHOCYTES; OLAPARIB MAINTENANCE THERAPY; PROGNOSTIC-SIGNIFICANCE; ANTI-PD-1; ANTIBODY; ANTITUMOR-ACTIVITY; CLINICAL ACTIVITY; SOLID TUMORS; PHASE-II; T-CELLS; SAFETY;
D O I：
10.3390/diagnostics10030146
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers. Despite improvements in medical treatments, the prognosis for EOC remains poor, and there is an urgent need for new therapeutic strategies. Immune checkpoint inhibitors (CPIs) have dramatically improved survival of several cancers and are under evaluation in OC. Unfortunately, CPIs have shown globally unsatisfactory results. The aim of this manuscript is to critically review the results from early-phase trials with CPIs in terms of safety and activity, discuss the possible reasons for disappointing results and the new therapeutic approaches to improve patient outcomes.
引用
收藏
页数：17
相关论文
共 76 条
  • [1] Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
    Alme, Angela K. B.
    Karin, Beerinder S.
    Faltas, Bishoy M.
    Drake, Charles G.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (04) : 171 - 181
  • [2] American College Health Association, 2020, CONS REOP I HIGH ED, P20
  • [3] [Anonymous], P 17 BIENN M INT GYN
  • [4] First-line PARP inhibition in ovarian cancer - standard of care for all?
    Banerjee, Susana N.
    Lord, Christopher J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) : 136 - 137
  • [5] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [7] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer, Julie R.
    Drake, Charles G.
    Wollner, Ira
    Powderly, John D.
    Picus, Joel
    Sharfman, William H.
    Stankevich, Elizabeth
    Pons, Alice
    Salay, Theresa M.
    McMiller, Tracee L.
    Gilson, Marta M.
    Wang, Changyu
    Selby, Mark
    Taube, Janis M.
    Anders, Robert
    Chen, Lieping
    Korman, Alan J.
    Pardoll, Drew M.
    Lowy, Israel
    Topalian, Suzanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3167 - 3175
  • [8] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
    Buchbinder, Elizabeth I.
    Desai, Anupam
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 98 - 106
  • [9] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
  • [10] Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
    Champiat, Stephane
    Ileana, Ecaterina
    Giaccone, Giuseppe
    Besse, Benjamin
    Mountzios, Giannis
    Eggermont, Alexander
    Soria, Jean-Charles
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 144 - 153
12345678